Change in CellaVision's Nomination Committee for the Annual General Meeting 2027

CellaVision AB (publ) today announces a change in the company's Nomination Committee for the Annual General Meeting 2027. SEB Funds appointed Anette Andersson as representative replacing Erik Ståhl Hallengren.

After the change, the Nomination Committee consists of the following members:
- Nicklas Hansen, William Demant Invest A/S
- Joel Eklund, Grenlunden CEVI AB (Chairman of the Nomination Committee)
- Christer Fåhraeus, Christer Fåhraeus with Companies
- Anette Andersson, SEB Funds

The CellaVision Annual General Meeting 2027 will be held on May 4, 2027 at 15:00 o'clock CEST, in Lund.

Shareholders wishing to have matters considered at the Annual General Meeting can send a written request by email to: ir@cellavision.com, or ordinary mail addressed to: The Board of Directors, CellaVision AB, Mobilvägen 12, 223 62 Lund. The request must have been received at the latest seven weeks before the Annual General Meeting in order to be included in the notice to attend and thus the agenda of the Annual General Meeting.

Contact

Lisa Bodily Nordqvist
Investor Relations and Corporate Communications Manager
Phone: + 46 76 345 31 87
E-mail: lisa.bodilynordqvist@cellavision.com
www.cellavision.com

About Us

CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. These analyses play a vital role in swift and accurate disease diagnoses, particularly in cases of infections and serious cancer diseases. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company's 13 local market support organizations covering more than 40 countries. In 2025, sales were SEK 759 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

Attachments

Change in CellaVision's Nomination Committee for the Annual General Meeting 2027